The U.S. health regulator said on March 25 the current authorized dose of GlaxoSmithKline and Vir Biotechnology’s COVID-19 antibody therapy is unlikely to be effective against the Omicron BA.2 variant.
An antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralizing activity against the emerging BA.2 form of the Omicron coronavirus variant, according to data from a laboratory study cited by Vir on February 10.
People who die of severe COVID-19 have brain abnormalities that resemble changes seen in Alzheimer’s disease – accumulation of a protein called tau inside brain cells, and abnormal amounts of the protein beta-amyloid that accumulates into amyloid plaques – small studies found. In other news, seniors can safely get the high-dose flu vaccine and an mRNA COVID-19 booster dose at the same time, a new study confirms.
To challenge the status quo reporting of mass-shootings, the Columbia Journalism Review (CJR) is bringing together some of the biggest names in journalism to help chart a new path forward for covering mass shootings.
Laboratory testing found that Regeneron Pharmaceuticals Inc.’s Covid-19 antibody cocktail can combat a coronavirus variant first found in South Africa, but a similar drug from Eli Lilly and Co. is inactive against it, according to a study.
The number of coronavirus deaths reported in the United States reached its highest total in two months, offering more evidence that the pandemic was gaining fresh momentum across the country as cooler weather sets in.
In a study published in Nature Medicine, scientists at Columbia University and Vanderbilt University describe how they were able to successfully restore badly damaged lungs in order to use them for lung transplants.
Researchers at Boston University and Signify confirmed that UV-C light effectively eradicates the SARS-CoV-2 virus.
Boston Biomedical Inc. entered into an alliance in oncology research with three world-leading oncology centers of excellence – Columbia University, Harvard University and The Wistar Institute.
Researchers with NYC’s Columbia University published research showing how one of the genes that has definitely been tied to schizophrenia, SETD1A, works to increase risk of the disease.
